The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate

Journal of Cardiovascular Pharmacology

Volumn 59, Issue 3, 2012, Pages 254-259

  Shen, Jian ^a,b   Arnett, Donna K ^c   Parnell, Laurence D ^b   Lai, Chao Qiang ^b   Straka, Robert J ^d   Hopkins, Paul N ^e   An, Ping ^f   Feitosa, Mary F ^f   Ordovás, José M ^b  

^a OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^b TUFTS UNIVERSITY   (United States)

^c UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

^d UNIVERSITY OF MINNESOTA   (United States)

^e UNIVERSITY OF UTAH   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

CYP7A1; fenofibrate; polymorphism; TG response

Indexed keywords

CHOLESTEROL 7ALPHA MONOOXYGENASE; FENOFIBRATE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; ARTICLE; DRUG MECHANISM; FEMALE; GENETIC ASSOCIATION; GENETIC VARIABILITY; GENOTYPE; HOMOZYGOTE; HUMAN; LIPID ANALYSIS; MAJOR CLINICAL STUDY; MALE; MORNING DOSAGE; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; TREATMENT RESPONSE;

ADULT; AGED; ALLELES; CHOLESTEROL 7-ALPHA-HYDROXYLASE; CHOLESTEROL, HDL; EUROPEAN CONTINENTAL ANCESTRY GROUP; FEMALE; FENOFIBRATE; GENETIC VARIATION; HOMOZYGOTE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; TRIGLYCERIDES;

EID: 84858796882     PISSN: 01602446     EISSN: 15334023     Source Type: Journal    
DOI: 10.1097/FJC.0b013e31823de86b     Document Type: Article

References (37)

1. Russell DW, Setchell KD. Bile acid biosynthesis. Biochemistry. 1992;31: 4737-4749.
2. Angelin B, Einarsson K, Hellstrom K, et al. Bile acid kinetics in relation to endogenous triglyceride metabolism in various types of hyperlipopro-teinemia. J Lipid Res. 1978;19:1004-1016. (Pubitemid 9059812)
3. Bertolotti M, Abate N, Bertolotti S, et al. Effect of aging on cholesterol 7 alpha-hydroxylation in humans. J Lipid Res. 1993;34:1001-1007. (Pubitemid 23182697)
4. Spady DK, Cuthbert JA, Willard MN, et al. Overexpression of cholesterol 7alpha-hydroxylase (CYP7A) in mice lacking the low density lipoprotein (LDL) receptor gene. LDL transport and plasma LDL concentrations are reduced. J Biol Chem. 1998;273:126-132. (Pubitemid 28042185)
5. Pullinger CR, Eng C, Salen G, et al. Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest. 2002;110:109-117. (Pubitemid 34743471)
6. Post SM, Groenendijk M, Solaas K, et al. Cholesterol 7alpha-hydroxylase deficiency in mice on an APOE*3-Leiden background impairs very-low-density lipoprotein production. Arterioscler Thromb Vasc Biol. 2004;24:768-774. (Pubitemid 38451618)
7. Miyake JH, Doung XD, Strauss W, et al. Increased production of apo-lipoprotein B-containing lipoproteins in the absence of hyperlipidemia in transgenic mice expressing cholesterol 7alpha-hydroxylase. J Biol Chem. 2001;276:23304-23311.
8. Couture P, Otvos JD, Cupples LA, et al. Association of the A-204C polymorphism in the cholesterol 7alpha-hydroxylase gene with variations in plasma low density lipoprotein cholesterol levels in the Framingham Offspring Study. J Lipid Res. 1999;40:1883-1889. (Pubitemid 29477259)
9. Teslovich TM, Musunuru K, Smith AV, et al. Biological, clinical and population relevance of 95 loci for blood lipids. Nature. 466:707-713.
10. Wang J, Freeman DJ, Grundy SM, et al. Linkage between cholesterol 7alpha-hydroxylase and high plasma low-density lipoprotein cholesterol concentrations. J Clin Invest. 1998;101:1283-1291. (Pubitemid 28145244)
11. Barcelos AL, Chies R, Almeida SE, et al. Association of CYP7A1-278A.C polymorphism and the response of plasma triglyceride after dietary intervention in dyslipidemic patients. Braz J Med Biol Res. 2009; 42:487-493.
12. Hofman MK, Weggemans RM, Zock PL, et al. CYP7A1 A-278C polymorphism affects the response of plasma lipids after dietary cholesterol or cafestol interventions in humans. J Nutr. 2004;134:2200-2204. (Pubitemid 39201585)
13. Birjmohun RS, Hutten BA, Kastelein JJ, et al. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol. 2005;45:185-197. (Pubitemid 40094724)
14. Post SM, Duez H, Gervois PP, et al. Fibrates suppress bile acid synthesis via peroxisome proliferator-activated receptor-alpha-mediated downregula-tion of cholesterol 7alpha-hydroxylase and sterol 27-hydroxylase expression. Arterioscler Thromb Vasc Biol. 2001;21:1840-1845. (Pubitemid 34219790)
15. Higgins M, Province M, Heiss G, et al. NHLBI Family Heart Study: objectives and design. Am J Epidemiol. 1996;143:1219-1228. (Pubitemid 26178734)
16. Lai CQ, Arnett DK, Corella D, et al. Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study. Arterioscler Thromb Vasc Biol. 2007;27:1417-1425. (Pubitemid 46809433)
17. Wojczynski MK, Gao G, Borecki I, et al. Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study. J Lipid Res. 51:3316-3323.
18. Otvos JD. Measurement of lipoprotein subclass profiles by nuclear magnetic resonance spectroscopy. Clin Lab. 2002;48:171-180. (Pubitemid 34272531)
19. Barrett JC, Fry B, Maller J, et al. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics. 2005;21:263-265. (Pubitemid 40202029)
20. Staels B, Dallongeville J, Auwerx J, et al. Mechanism of action of fibrates on lipid and lipoprotein metabolism. Circulation. 1998;98:2088-2093. (Pubitemid 28512236)
21. Kajinami K, Brousseau ME, Ordovas JM, et al. A promoter polymorphism in cholesterol 7alpha-hydroxylase interacts with apolipoprotein E genotype in the LDL-lowering response to atorvastatin. Atherosclerosis. 2005;180:407-415. (Pubitemid 41072913)
22. Poduri A, Khullar M, Bahl A, et al. Common variants of HMGCR, CETP, APOAI, ABCB1, CYP3A4, and CYP7A1 genes as predictors of lipid-lowering response to atorvastatin therapy. DNA Cell Biol. 29:629-637.
23. Hofman MK, Princen HM, Zwinderman AH, et al. Genetic variation in the rate-limiting enzyme in cholesterol catabolism (cholesterol 7alpha-hydroxylase) influences the progression of atherosclerosis and risk of new clinical events. Clin Sci (Lond). 2005;108:539-545. (Pubitemid 40827562)
24. Marrapodi M, Chiang JY. Peroxisome proliferator-activated receptor alpha (PPARalpha) and agonist inhibit cholesterol 7alpha-hydroxylase gene (CYP7A1) transcription. J Lipid Res. 2000;41:514-520. (Pubitemid 30220654)
25. Nakamoto K, Wang S, Jenison RD, et al. Linkage disequilibrium blocks, haplotype structure, and htSNPs of human CYP7A1 gene. BMC Genet. 2006;7:29.
26. Crestani M, Sadeghpour A, Stroup D, et al. Transcriptional activation of the cholesterol 7alpha-hydroxylase gene (CYP7A) by nuclear hormone receptors. J Lipid Res. 1998;39:2192-2200. (Pubitemid 28523125)
27. Lenicek M, Komarek V, Zimolova M, et al. CYP7A1 promoter polymorphism-203A.C affects bile salt synthesis rate in patients after ileal resection. J Lipid Res. 2008;49:2664-2667.
28. Liang G, Yang J, Horton JD, et al. Diminished hepatic response to fasting/refeeding and liver X receptor agonists in mice with selective deficiency of sterol regulatory element-binding protein-1c. J Biol Chem. 2002;277:9520-9528. (Pubitemid 34953041)
29. Wang SL, Du EZ, Martin TD, et al. Coordinate regulation of lipogenesis, the assembly and secretion of apolipoprotein B-containing lipoproteins by sterol response element binding protein 1. J Biol Chem. 1997;272: 19351-19358. (Pubitemid 27337730)
30. Watanabe M, Houten SM, Wang L, et al. Bile acids lower triglyceride levels via a pathway involving FXR, SHP, and SREBP-1c. J Clin Invest. 2004;113:1408-1418. (Pubitemid 39071696)
31. Machleder D, Ivandic B, Welch C, et al. Complex genetic control of HDL levels in mice in response to an atherogenic diet. Coordinate regulation of HDL levels and bile acid metabolism. J Clin Invest. 1997;99: 1406-1419. (Pubitemid 27142779)
32. Lefebvre P, Cariou B, Lien F, et al. Role of bile acids and bile acid receptors in metabolic regulation. Physiol Rev. 2009;89:147-191.
33. Keech A, Simes RJ, Barter P, et al. Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial. Lancet. 2005; 366:1849-1861.
34. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol. Veterans Affairs High-Density Lipopro-tein Cholesterol Intervention Trial Study Group. N Engl J Med. 1999; 341:410-418. (Pubitemid 29362514)
35. Barter PJ, Rye KA. Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome? Arterioscler Thromb Vasc Biol. 2008;28:39-46.
36. Higgins M. Epidemiology and prevention of coronary heart disease in families. Am J Med. 2000;108:387-395. (Pubitemid 30162957)
37. Otvos J. Measurement of triglyceride-rich lipoproteins by nuclear magnetic resonance spectroscopy. Clin Cardiol. 1999;22(suppl):II21-II27. (Pubitemid 29265096)